Clinical trials: Diabetes Type I
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Evaluation of Updated Continuous Glucose Monitoring (CGM) Form Factor in Adults, Adolescents and Pediatrics
The purpose of this study is to demonstrate the performance of the Disposable Sensor (DS5) in subjects age 2 - 80 years, for the span of 170 hours (7 days).
- Trial name
- NCT04436822
- Testing
- Continuous Glucose Monitoring
- Where
- 18 sites in United States, China
- Volunteers
- 317 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes Type 1
CGM Precision and Glycaemic Variability
Use of devices for continuous monitoring of the blood sugar is valuable for people with diabetes to understand their disease and to help prevent low blood sugar.
- Trial name
- NCT03842683
- Testing
- CGM
- Volunteers
- 472 people
- Sponsor
- Peter Vestergaard
Type 1 Diabetes Mellitus
Steroid-free and Long-term Calcineurin-free Trial in Islet Cell Transplantation
The purposes of this study are: 1. To reverse hyperglycemia and insulin dependency in patients with type 1 diabetes mellitus through islet transplantation utilizing steroid free, calcineurin-inhibitor free immunosuppression. 2.
- Trial name
- NCT00315627
- Testing
- Islet transplantation
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Rodolfo Alejandro
Type 1 Diabetes
In Clinic Evaluation of the PLGM Feature
This study is a multi-center, single arm and in-clinic study to evaluate the safety of the PLGM System and its algorithm with the Enlite 3 Sensor.
- Trial name
- PLGM (NCT02130284)
- Testing
- Predictive Low Glucose Management Feature in Insulin pump
- Where
- 8 sites in United States
- Volunteers
- 80 people
- Sponsor
- Medtronic MiniMed, Inc.
Type 1 Diabetes, Hypoglycemia
Islet Allotransplantation With Steroid Free Immunosuppression
The restoration of endogenous insulin secretion carries significant hopes for shifting the paradigm of life long exogenous insulin therapy in selected groups of patients with type 1 diabetes(T1D).
- Conditions
- Type 1 Diabetes, Hypoglycemia, Metabolic Diseases
- Trial name
- NCT00446264
- Testing
- islet transplantation, daclizumab - sirolimus - tacrolimus
- Where
- France
- Volunteers
- 14 people
- Sponsor
- University Hospital, Lille
Type 1 Diabetes Mellitus, Hypoglycemia
Raptiva and Sirolimus in Islet Transplantation for Type 1 Diabetes
The primary objective of this protocol is to test the safety and efficacy of a treatment regimen consisting of maintenance therapy with efalizumab and sirolimus for 1 year followed by withdrawal of efalizumab and maintenance…
- Trial name
- RAPTIVA (NCT00672204)
- Testing
- Allogeneic islets of Langerhans transplant, Raptiva, Sirolimus
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Minnesota
Diabetes Mellitus, Type I, Diabetes Mellitus, Insulin-Dependent, 1
Imatinib Treatment in Recent Onset Type 1 Diabetes Mellitus
Type 1 diabetes mellitus (T1DM) results from the autoimmune destruction of insulin-producing ß cells. Although exogenous insulin is widely available, it is not possible for affected individuals to consistently achieve euglycemia…
- Conditions
- Diabetes Mellitus, Type I, Diabetes Mellitus, Insulin-Dependent, 1, Type 1 Diabetes Mellitus, Insulin-Dependent Diabetes Mellitus 1
- Trial name
- NCT01781975
- Testing
- Imatinib Mesylate
- Where
- 9 sites in United States, Australia
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Metastatic Pancreatic Adenocarcinoma
FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer
This study will enroll patients who have metastatic pancreatic cancer with stable disease on FOLFIRINOX chemotherapy. The main purpose of this study is to compare survival between patients that receive ipilimumab and a pancreatic…
- Trial name
- NCT01896869
- Testing
- Ipilimumab, Vaccine, FOLFIRINOX
- Where
- 3 sites in United States
- Volunteers
- 83 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Type 1 Diabetes Mellitus
Omnipod Horizon™ Automated Glucose Control System Preschool Cohort
Subjects will undergo a 14-day outpatient, standard therapy phase during which sensor and insulin data will be collected. This will be followed by a 94-day (13-week) hybrid closed-loop phase conducted in an outpatient setting…
- Trial name
- NCT04476472
- Testing
- Omnipod Horizon™ Automated Glucose Control System
- Where
- 10 sites in United States
- Volunteers
- 80 people
- Sponsor
- Insulet Corporation
Diabetes Mellitus, Type 1
ACCU-CHEK Connect Personal Diabetes Management Study (PDM CONNECT)
This post-market, interventional, prospective, single arm, the United States (US) based multi-center study will assess the change in treatment satisfaction of participants who utilize the ACCU-CHEK Connect Diabetes Management…
- Trial name
- NCT02600845
- Testing
- ACCU-CHEK
- Where
- 11 sites in United States
- Volunteers
- 122 people
- Sponsor
- Hoffmann-La Roche
Type 1 Diabetes Mellitus
Feasibility Study of Closed Loop Control in Type 1 Diabetes Using Heart Rate Monitoring as an Exercise Marker
The purpose of this study is to see if the Artificial Pancreas Platform (AP Platform = Cell Phone + Closed Loop Control) can successfully control blood sugar in people with type 1 diabetes mellitus on insulin pump therapy in a…
- Trial name
- NCT01582139
- Testing
- Heart rate informed SSM+HMM
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Virginia
Diabetes Mellitus
A Pivotal Study to Evaluate Guardian™ Connect CGM System Performance in China
The purpose of this study is to demonstrate the performance and safety of the Guardian™ Sensor (3) over 170 hours (7 days) when inserted in the abdomen used in subjects age 14 - 75 years with the Guardian™ Connect System.
- Trial name
- NCT03710083
- Testing
- Guardian™ Sensor (3)
- Where
- 3 sites in China
- Volunteers
- 72 people
- Sponsor
- Medtronic MiniMed, Inc.
Type 1 Diabetes
Effect of Metformin on Vascular and Mitochondrial Function in Type 1 Diabetes
Insulin resistance (IR) is an important contributor to increased cardiovascular disease risk in type 1 diabetes (T1D). The purpose of this study is to measure the effect of metformin on insulin sensitivity, vascular function and…
- Trial name
- MeT1 (NCT01813929)
- Testing
- Metformin
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Colorado, Denver
Type 1 Diabetes
Measurement of Glucose/Glycogen Metabolism in Humans Using Magnetic Resonance at 4 or 7 Tesla
The long-range goal of this project is to determine the effects of diabetes and the hypoglycemic consequences of intensive therapy on in vivo brain glucose metabolism in humans.
- Trial name
- Glycogen (NCT00786825)
- Testing
- somatostatin
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Diabetes Mellitus, Type 1
Avoidance of Hyperglycaemia in People With Type 1 Diabetes
This study aims to learn more about avoidance of hyperglycaemia in adults with type 1 diabetes. People who attend a type 1 diabetes clinic will be invited to complete a number of self-report questionnaires and a survey.
- Trial name
- HYPE (NCT04732780)
- Testing
- No intervention
- Where
- United Kingdom
- Volunteers
- 253 people
- Sponsor
- Imperial College London
Diabetes, Diabetes Mellitus, Type 1
Comparison of NN1250 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes
This trial is conducted in Asia, Europe, Japan and South America. The aim of the trial is to compare the efficacy, safety and tolerability of NN1250 (insulin degludec ([Deg]) with insulin detemir (IDet), both combined with…
- Trial name
- BEGIN™ (NCT01074268)
- Testing
- insulin degludec, insulin detemir, insulin aspart
- Where
- 69 sites in Argentina, Brazil and 6 more
- Volunteers
- 456 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
Safety of Insulin Detemir Produced by a New Process as Measured by Antibody Formation in Subjects With Type 1 Diabetes
The trial was conducted in Germany, The Republic of Macedonia, Russian Federation, Serbia and South Africa. The aim of this trial was to make a safety comparison of insulin detemir produced by a new production method (NN729) with…
- Trial name
- NCT00447382
- Testing
- insulin detemir, insulin aspart
- Where
- 5 sites in Germany, North Macedonia and 3 more
- Volunteers
- 330 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes
Artificial Pancreas in Pediatric Patients (PEDarPAN)
The purpose of this study is to determine safety, feasibility and efficacy (with respect to sensor- augmented pump therapy) of an Artificial Pancreas (AP) prototype in day and night closed-loop control in children and adolescents…
- Trial name
- PEDarPAN (NCT02620878)
- Testing
- artificial pancreas, sensor augmented pump
- Where
- Italy
- Volunteers
- 48 people
- Sponsor
- University of Padova
Type 1 Diabetes Mellitus
Closed Loop Control in Adolescents Using Heart Rate as Exercise Indicator
The purpose of this study is to see if the Artificial Pancreas (AP) Platform can successfully control blood sugar in people with type 1 diabetes mellitus on insulin pump therapy in a hospital setting.
- Trial name
- NCT01945060
- Testing
- heart rate Control to Range System (hrCTR) using DiAs Platform, DiAs Control-to-Range System not informed for heart rate
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Marc Breton
Type 1 Diabetes, Type 2 Diabetes
Nurse Telephone Management of Cholesterol in Diabetes
The current project is evaluating the effect of a nurse-administered phone care in diabetes to improve access to care and healthcare delivery.
- Trial name
- NATCHOS (NCT00950963)
- Testing
- Phone Counseling, Standard Clinical Care
- Where
- United States
- Volunteers
- 762 people
- Sponsor
- Denver Health and Hospital Authority